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Apoptotic human cells inhibit migration  
of granulocytes via release of lactoferrin
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Queen’s Medical Research Institute, Edinburgh, United Kingdom. 2ImmunoSolv Ltd., Edinburgh, United Kingdom.
Apoptosis	is	a	noninflammatory,	programmed	form	of	cell	death.	One	mechanism	underlying	the	non-phlo-
gistic	nature	of	the	apoptosis	program	is	the	swift	phagocytosis	of	the	dying	cells.	How	apoptotic	cells	attract	
mononuclear	phagocytes	and	not	granulocytes,	the	professional	phagocytes	that	accumulate	at	sites	of	inflam-
mation,	has	not	been	determined.	Here,	we	show	that	apoptotic	human	cell	lines	of	diverse	lineages	synthesize	
and	secrete	lactoferrin,	a	pleiotropic	glycoprotein	with	known	antiinflammatory	properties.	We	further	demon-
strated	that	lactoferrin	selectively	inhibited	migration	of	granulocytes	but	not	mononuclear	phagocytes,	both	in	
vitro	and	in	vivo.	Finally,	we	were	able	to	attribute	this	antiinflammatory	function	of	lactoferrin	to	its	effects	on	
granulocyte	signaling	pathways	that	regulate	cell	adhesion	and	motility.	Together,	our	results	identify	lactofer-
rin	as	an	antiinflammatory	component	of	the	apoptosis	milieu	and	define	what	we	believe	to	be	a	novel	antiin-
flammatory	property	of	lactoferrin:	the	ability	to	function	as	a	negative	regulator	of	granulocyte	migration.
Introduction
Apoptosis is a programmed, physiological form of cell death that, 
in inflammatory terms, is quiet: apoptotic cells are rapidly phago-
cytosed by their neighbors or by mononuclear phagocytes that are 
attracted by chemotactic factors such as lysophosphatidylcholine 
(1) and fractalkine (2) released by apoptotic cells. The rapid engulf-
ment of apoptotic cells militates against the potential tissue-injur-
ing and proinflammatory features of dead cells as exemplified by 
necrosis (3–6). Indeed, failed or delayed clearance of apoptotic cells 
can have detrimental inflammatory consequences, including the 
development of autoimmune pathologies (7–9). The mechanisms 
underlying the non- or antiinflammatory nature of the apoptosis 
program are not understood in detail. Antiinflammatory media-
tors such as TGF-β1 and IL-10 are known to be produced at sites 
of apoptosis, both directly by apoptotic cells themselves and indi-
rectly through interaction of apoptotic cells with phagocytes (10, 
11). Apoptotic cells selectively attract mononuclear phagocytes 
(1, 12), but, curiously, the other class of professional phagocytes, 
granulocytes or polymorphonuclear phagocytes, do not migrate 
toward apoptotic cells in vitro (12) and do not normally engage in 
apoptotic cell engulfment. The absence of granulocytes from sites 
of homeostatic and developmental apoptosis suggests that apop-
totic cells have the potential to selectively regulate the recruitment 
of mononuclear leukocytes.
In marked contrast to sites of apoptosis, sites of acute infection 
are characterized by the presence of granulocytes, most commonly 
neutrophils, as a means to protect the host by engulfing, killing, 
and digesting invading infectious agents. Neutrophils, as a first 
line of immune defense, are rapidly recruited to the site of infec-
tion in response to a variety of inflammatory stimuli, including 
chemokines, cytokines, leukotrienes, and bacterial components 
such as LPS and N-formylated peptides (13, 14). Comparative stud-
ies on the slime mold Dictyostelium discoideum have shown that in 
response to chemoattractants, neutrophils orient themselves and 
migrate in an “ameboid motion” by anterior pseudopod extension 
accompanied by simultaneous posterior contraction and retrac-
tion. Such polarized morphology is characterized by the forma-
tion of a lamellipodium at the leading edge and a uropod at the 
trailing edge of the neutrophil (15–18). This process is tightly con-
trolled not only to ensure the efficient migration of neutrophils to 
inflammatory sites, but also to prevent their aberrant infiltration 
and consequent tissue-damaging activities. Detrimental effects of 
neutrophils — caused, for example, by release of their proteolytic 
enzymes — contribute to many pathological inflammatory condi-
tions, ranging from vasculitis and ischemia/reperfusion injury to 
glomerulonephritis, rheumatoid arthritis, and acute graft rejection 
(19). Therefore, at inflammatory sites, negative signals exist that 
prevent neutrophil recruitment, dampen neutrophil responsive-
ness, and counterbalance or terminate the inflammatory response. 
This antiinflammatory program is characterized by cessation of 
neutrophil infiltration, as arachidonic acid–derived prostaglan-
dins and leukotrienes are switched to lipoxins, resolvins, and pro-
tectins (20, 21). Resolution of inflammation is ultimately achieved 
through neutrophil apoptosis, and apoptotic neutrophils are sub-
sequently phagocytosed by macrophages, a process that leads to 
the release not only of antiinflammatory cytokines but also of such 
antiinflammatory and proresolving lipid mediators as lipoxin A4, 
resolvin E1, and protectin D1 (22–25).
Given (a) the production of negative signaling molecules at 
inflammatory sites to limit neutrophil recruitment and func-
tion and (b) failure of neutrophil migration to sites of apoptosis, 
we sought to determine whether apoptotic cells actively produce 
negative regulators of neutrophil chemotaxis. We postulated that 
the production by apoptotic cells of factors that inhibit neutro-
phil migration contribute to the non-phlogistic nature of the 
apoptosis program. Here, we present evidence that apoptotic cells 
actively inhibit neutrophil migration through the production of 
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lactoferrin, an 80 kDa antiinflammatory glycoprotein that spe-
cifically inhibits chemotaxis of neutrophils but not mononuclear 
phagocytes. Lactoferrin was found to be synthesized de novo fol-
lowing triggering of apoptosis and released by apoptotic cells 
of diverse lineages. Lactoferrin impaired neutrophil activation 
and prevented mobilization of the cells by inhibiting migratory 
polarization of the cell body. These results demonstrate that the 
non-phlogistic constitution of apoptotic cells includes an anti-
inflammatory molecule, lactoferrin, that we show, for the first 
time to our knowledge, has potent negative regulatory effects on 
neutrophil migration. These findings provide a rationale for the 
absence of neutrophils from apoptotic sites and have important 
implications for understanding the mechanisms involved in the 
resolution phase of inflammation.
Results
Apoptotic cells actively produce factor(s) that inhibit neutrophil chemotaxis. 
To address whether apoptotic cells influence migratory activ-
ity of neutrophils, we carried out a series of in vitro Boyden-type 
chemotaxis assays to investigate neutrophil migration toward 
Burkitt lymphoma (BL) cells. We initially employed BL as a model 
tissue as these tumor cell populations display high levels of apop-
tosis, a property that is retained constitutively in the tumor-derived 
cell lines. As at all sites of apoptosis, there is marked infiltration of 
macrophages that engulf the apoptotic cells, giving rise to the typi-
cal “starry sky” histological appearance of this tumor. As shown in 
Figure 1A (left), while macrophages were abundant in histological 
sections of BL, neutrophils were absent. We assessed the effects of 
BL cells on the migratory activity of neutrophils in vitro by add-
ing neutrophils to the top compartment of a Transwell filter and 
inducing them to migrate toward the lower chamber containing BL 
cells in the presence of the powerful neutrophil chemoattractant 
formyl-methionyl-leucyl-phenylalanine (fMLP) (Figure 1B). As 
shown in Figure 1C, neutrophil migration was significantly inhib-
ited in BL cells in a concentration-dependent manner. We observed 
a similar effect irrespective of the chemoattractant used (inhibition 
of neutrophil migration induced by C5a, IL-8, and leukotriene B4 
[LTB4]; data not shown, but see below). We carried out subsequent 
chemotaxis assays using BL-conditioned medium obtained over 
a 7-hour time course and found that BL cells actively released an 
inhibitory factor(s) (Figure 1D). The release of the inhibitory fac-
tor appeared to be linked to the levels of apoptosis in the BL cell 
populations, since the inhibitory activity was significantly lower in 
further chemotaxis assays using BL-conditioned medium derived 
from cells overexpressing the apoptosis inhibitor Bcl-2, as com-
pared with that of parental cells (Figure 1E).
Biochemical characterization of neutrophil migration–inhibitory 
factor(s). In an attempt to gain further insight into the biochemi-
cal nature of the factor(s) that BL cells secrete in order to exclude 
neutrophils from their environment, we initially estimated the 
molecular weight range of the inhibitory factor(s) by using filters 
with molecular weight cutoff points of approximately 3, 10, 30, 
50, and 100 kDa. BL-conditioned media obtained after 24-hour 
incubation were fractionated, and each fraction was examined in 
vitro using the neutrophil chemotaxis assay described above. The 
results revealed that fractions containing molecules of less than 
50 kDa failed to display any inhibitory effect on neutrophil migra-
tion (Figure 2A). However, the use of 100 kDa filters revealed that 
both fractions (>100 kDa and <100 kDa) displayed an inhibitory 
effect on neutrophil migration, indicating that at least 1 factor 
has a molecular weight that ranges between 50 and 100 kDa. 
The presence of inhibitory activity in the filtrate of the 100 kDa 
Figure 1
Apoptotic cells release factor(s) that inhibit neutrophil migration. (A) Immunohistochemical analysis of neutrophils in BL (left) and spleen (positive 
control; right) sections. Inset images represent isotype control. (B) Representative images of stained Transwell filters. (C) Neutrophil chemotaxis 
toward increasing concentrations of BL cells was assessed in the presence of fMLP (100 nM). n = 3; *P < 0.05 vs. time 0. (D) BL cell–conditioned 
media obtained at the indicated time points were used to analyze fMLP-induced neutrophil chemotaxis. n = 3; *P < 0.05 vs. fMLP. (E) Neutrophil 
chemotaxis toward fMLP was analyzed in the presence of control or Bcl-2–transfected BL2 cells obtained following a 0- and 5-hour incubation 
at 37°C. n = 3; *P < 0.05 vs. BL2 0 h; NS vs. BL2/Bcl-2 0 h. Apoptosis levels were assessed by flow cytometry following staining with annexin V/ 
propidium iodide. Error bars indicate SEM. Original magnification; ×400 (A; A, insets; B). hpf, high-power field.
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cutoff membrane is likely to result from (a) imprecise molecular 
weight cutoff of molecules in the 50–100 kDa range, (b) complex 
formation through multimerization of the 50–100 kDa factor or 
through interaction with other molecules, or (c) the existence of a 
distinct inhibitory activity of greater than 100 kDa. It should be 
noted that the selected isolation approach is skewed in favor of 
proteins and that additional low-molecular-weight (for example, 
lipid) mediators of neutrophil migration inhibition would not be 
identified by these procedures.
To investigate further the biochemical properties of the reten-
tate and filtrate of the 100 kDa cutoff membrane, we first deter-
mined the charge (pI value) of the migration-inhibitory activity 
by means of an ion exchange analysis of BL-conditioned media. 
Using positively charged ion exchange beads (Q Sepharose), the 
100 kDa membrane retentate and filtrate were separated into posi-
tively charged (Q-supernatant) and negatively charged (Q-eluant) 
fractions. As shown in Figure 2B, the filtrate of the 100 kDa mem-
brane (<100 kDa fraction) contained migration-inhibitory activity 
in both the supernatant (positive charge) and the eluant (nega-
tive charge) of the Q beads. By contrast, analyses of the retentate 
(>100 kDa fraction) revealed that only the negatively charged elu-
ant displayed significant activity in inhibiting neutrophil migra-
tion. These results indicate that at least 2 moieties with neutrophil 
migration–inhibitory activity were present in BL cell–conditioned 
medium: one of 50–100 kDa with positive pI and a second of 
100 kDa or more and negatively charged.
We subsequently determined whether the neutrophil migration–
inhibitory activity was heat labile. As shown in Figure 2C, heat 
inactivation completely abrogated all chemotaxis inhibitory activ-
ity in BL cell–conditioned medium, suggesting that the inhibitory 
Figure 2
Biochemical characterization of the inhibitory factor. Conditioned media from BL2 cells cultured for 24 hours were size fractionated using filters 
with 50 kDa (A) molecular weight cutoff sizes. Unfiltered medium was included as control. *P < 0.001 compared with the corresponding positive 
control. Error bars indicate SEM. Ion exchange analysis included the use of Q Sepharose beads (positively charged) in order to distinguish posi-
tively and negatively charged molecules in the <100 kDa fraction (B) of the BL medium. Unbound molecules (Q1 fraction) were collected, where-
as bound molecules were eluted from the beads (Q2 fraction). Neutrophil migration toward these fractions in the presence of fMLP (100 nM) 
was assessed. Q1 and Q2 fractions (unbound and eluant fraction) of serum-free medium (no BL) were included as control. †P < 0.05 compared 
with the corresponding control. Error bars indicate SEM. (C) Chemotaxis assay of neutrophils toward BL-conditioned medium that was heat 
inactivated (90°C for 10 minutes). (D) MALDI-TOF mass spectrum for the tryptic digest of the peptide band identified as lactoferrin.
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factor(s) were most likely protein in nature. We then analyzed the 
proteins released from BL cells in viable and apoptotic states by 
protein fingerprinting. Polypeptide bands of greater than 50 kDa 
were excised from a 10% SDS polyacrylamide gel. Tryptic peptides 
were gel extracted, and matrix-assisted laser desorption/ioniza-
tion–time of flight (MALDI-TOF) mass spectrometric analysis was 
carried out (Figure 2D). Also, given the crude biochemical char-
acteristics described above, we undertook a candidate approach 
based on the proteins released from apoptotic BL cells. We iden-
tified the factor released by BL cells that prevented neutrophil 
chemotaxis as lactoferrin.
Lactoferrin specifically inhibits neutrophil chemotaxis toward a range 
of chemoattractants. Lactoferrin is a glycoprotein of approximately 
75–80 kDa that belongs to the transferrin family of proteins due 
to its iron-binding properties. It is a well-characterized component 
of neutrophil secondary granules, lacrimal fluid, colostrum, saliva, 
and mucosal secretions, in which it confers antibacterial activity. 
We observed that addition of anti-lactoferrin antibody to BL-con-
ditioned medium neutralized its neutrophil migration–inhibi-
tory activity using either polyclonal or monoclonal antibodies 
(Figure 3A and Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI36226DS1). 
Similar results were observed with supernatants obtained from the 
mammary carcinoma line MCF-7, indicating that the neutrophil 
migration–inhibitory activity is not restricted to BL cell–derived 
lactoferrin (Figure 3B). Furthermore, lactoferrin purified from 
human milk displayed dose-dependent inhibitory activity toward 
neutrophil migration in response to fMLP (Figure 3E) and also 
inhibited migration toward C5a, IL-8, and LTB4 to similar levels 
(Figure 4A). The neutrophil migration–inhibitory effect was also 
displayed by lactoferrin purified from human neutrophils (Fig-
ure 4D). It should be noted that both types of purified lactoferrin 
used in this study were free of endotoxin contamination, and the 
observed inhibitory effect did not appear to be due to any lactofer-
rin-associated molecules such as LPS. Furthermore, inhibition of 
lactoferrin expression by shRNA in BL cells provides additional 
support for the specificity of the observed lactoferrin effect. 
Thus, we found that neutrophil chemotaxis toward supernatants 
obtained from BL2 cells transfected with shRNA vectors targeted 
against lactoferrin was higher compared with supernatants from 
BL control or mock-transfected cells (Figures 3, C and D). Lac-
toferrin exerted no toxic effects on neutrophils, as assessed by 
annexin V/propidium iodide staining of control and lactoferrin-
treated neutrophils (>98% cell viability). These results suggested 
that lactoferrin binds to neutrophils and inhibits their ability to 
undergo chemotaxis. To exclude the possibility that the observed 
inhibitory activity of lactoferrin was due instead to its ability to 
bind and functionally neutralize the chemoattractants, additional 
chemotaxis assays were performed using chemoattractants (fMLP, 
C5a, IL-8) that were preabsorbed with lactoferrin. To achieve this, 
we preincubated chemoattractants with lactoferrin. Subsequently, 
anti-lactoferrin antibody was used to remove the lactoferrin with 
the aid of magnetic beads. As shown in Figure 4B, no difference 
in neutrophil chemotactic activity was observed between the con-
trol and lactoferrin-absorbed chemoattractants, which excludes 
the possibility that lactoferrin binds to, and alters the activity of, 
the chemoattractants. Further supporting our conclusion that 
lactoferrin exerts its inhibitory effects through binding to neutro-
phils, we also observed that purified lactoferrin can directly associ-
ate with neutrophils (Figure 4C). In addition, Scatchard binding 
Figure 3
Lactoferrin specifically inhibits neutrophil chemotaxis. Neutrophil chemotaxis in the presence of human anti-lactoferrin (anti-LTF) polyclonal 
antibody (gray) or isotype control (black) using conditioned media from BL (A) and MCF7 (B) cells (A: n = 3, *P < 0.05 vs. isotype control, NS vs. 
fMLP anti-lactoferrin control; B; n = 3, †P < 0.001 vs. fMLP/isotype; NS vs. fMLP/anti-LTF. (C) RT-PCR analysis to assess lactoferrin expression 
in BL cells stably expressing LTF shRNA (LTF) cells and mock-transfected (mm) cells induced to become apoptotic (1 μM staurosporine; 37°C). 
(D) Chemotaxis assay to determine neutrophil migration toward supernatants obtained from control, LTF shRNA, and mock-transfected BL 
cells (n = 5; §P < 0.05 compared with mm shRNA control; **P < 0.05 compared with fMLP; NS compared with fMLP control). (E) Dose-response 
analysis of purified human lactoferrin. n = 3; ¶P < 0.05 vs. 0 g/ml purified LTF + fMLP. Error bars indicate SEM.
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analysis of 125I-labeled apolactoferrin indicated, in accordance with 
earlier findings (26, 27), that lactoferrin bound to neutrophils via 
2 classes of receptor that differ in affinity and number of binding 
sites per cell. We determined the higher-affinity receptors to be 
expressed at a density of 9,100 ± 2,500 binding sites per cell, with 
an affinity of 350 ± 65 nM, and the lower-affinity receptors to be 
expressed at a density of 2.5 × 106 ± 0.7 × 106 per cell, with an affin-
ity of 20 ± 10 μM (Supplemental Figure 2).
To determine whether the migration-inhibitory effects of lacto-
ferrin were specific to neutrophils among professional phagocytes, 
we analyzed its effects on monocyte and macrophage migration 
in vitro. As shown in Figure 4, E and F, C5a-induced chemotaxis 
of mononuclear phagocytes was unimpaired by lactoferrin. We 
further assessed whether lactoferrin acted by inhibiting neutro-
phil migration or promoting neutrophil repulsion. In chemotaxis 
assays, in which we added lactoferrin to the upper chamber along 
with neutrophils, we observed inhibition of neutrophil migration 
toward fMLP and control medium (Figure 4G), suggesting that 
lactoferrin exerts a direct effect on neutrophils by inhibiting their 
migratory ability and not by forcing them to migrate in all direc-
tions away from the chemoattractant.
Neutrophil migration–inhibitory effects of lactoferrin are not related 
to its iron-binding properties and are demonstrable in vitro and in vivo. 
Iron and iron-associated molecules have been previously shown 
to play an important role in many immunomodulatory functions. 
Indeed, suppression of IL-1 release by monocytes is observed by 
purified iron-saturated lactoferrin, whereas an inhibition of GM 
colony-stimulating activity production by monocytes and mac-
rophages correlated with the iron saturation status of lactoferrin 
(28–30). Therefore, we further examined whether differences in 
the iron saturation profile of lactoferrin affect its ability to inhibit 
neutrophil migration. Chemotaxis assays to determine neutro-
phil migration toward iron-depleted (apo-lactoferrin), partially 
iron-saturated, or fully iron-saturated (holo-lactoferrin) lactofer-
Figure 4
Neutrophil chemotaxis toward lactoferrin is irrespective of the chemoattractant used and its iron saturation status. (A) Neutrophil chemotaxis 
toward different chemoattractants. n = 3; *P < 0.05. (B) Neutrophil chemotaxis toward chemoattractants (control) or chemoattractants that were 
incubated with lactoferrin (10 μg/ml) followed by the addition of isotype or anti-lactoferrin monoclonal antibody (10 μg/ml). Antibodies were 
removed using magnetic IgG beads. n = 3; *P < 0.05, NS compared with chemoattractant control. (C) Immunoblot analysis of lysates of neu-
trophils incubated with or without biotinylated lactoferrin (10 μg/ml) at 37°C for 1 hour. (D) Neutrophil chemotaxis toward lactoferrin (10 μg/ml) 
purified from human neutrophils or human milk. **P < 0.001 vs. fMLP. C5a-induced monocyte (E) or macrophage (F) chemotaxis. (G) Neutrophil 
migration in the presence of lactoferrin (10 μg/ml) in the top or bottom compartment of the Transwell insert (n = 3; NS vs. corresponding +LTF 
controls). (H) Chemotaxis assay to determine neutrophil migration toward purified recombinant iron-depleted (Apo-), partially iron-saturated, and 
fully iron-saturated (Holo-) recombinant lactoferrin (10 μg/ml). Milk-purified lactoferrin and partially iron-saturated transferrin (TF; 10 μg/ml) were 
added as control. n = 4; †P < 0.001 compared with fMLP control. Error bars indicate SEM.
Downloaded on June 13, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/36226
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 1   January 2009 25
rin revealed that the level of iron saturation was not responsible 
for the observed inhibition in neutrophil migration (Figure 4H). 
Also, as lactoferrin belongs to the transferrin family of proteins 
sharing 74% sequence homology with transferrin (both of them 
are 80 kDa cationic iron-binding glycoproteins), we reasoned 
that, if the underlying neutrophil migration–inhibitory mecha-
nism of lactoferrin was rooted in its ability to chelate iron, trans-
ferrin might show similar effects on neutrophil migration. To 
explore this possibility, we performed chemotaxis assays in which 
neutrophils were induced to migrate toward fMLP in the pres-
ence of partially iron-saturated transferrin. Our results showed 
that transferrin, unlike lactoferrin, had no effect on neutrophil 
chemotaxis, further supporting the conclusion that the observed 
neutrophil migration–inhibitory effect is lactoferrin specific and 
is unlikely to require iron-chelating activity (Figure 4H).
Having established the inhibitory effects of lactoferrin on neutro-
phil chemotaxis in vitro, we then used a murine peritonitis model 
to assess the effect of lactoferrin on leukocyte recruitment in vivo. 
Lactoferrin and transferrin were tested for their ability to affect 
thioglycollate-induced leukocyte recruitment to the peritoneal 
cavity. As shown in Figure 5, A and B, thioglycollate caused rapid 
recruitment of leukocytes compared with vehicle alone, and the 
recruited leukocytes were predominantly neutrophils (88%). In the 
presence of lactoferrin, the total number of neutrophils recruited 
to the peritoneal cavity was reduced by 52% compared with con-
trol, whereas transferrin had no effect. Lactoferrin reduced specifi-
cally the proportion and number of neutrophils migrating into the 
cavity but did not affect recruitment of other types of leukocytes in 
response to thioglycollate (Figure 5C). These results demonstrate 
that, similar to its effect on neutrophil chemoattraction in vitro, 
lactoferrin is a potent inhibitor of neutrophil migration in vivo.
Impairment of neutrophil activation profile by lactoferrin. Neutrophil 
migration involves activation, adhesion, and extravasation pro-
cesses that are accompanied by gross changes in cell morphology: 
whereas nonactivated neutrophils are rounded, activated neutro-
phils acquire a polarized morphology with spreading and adhe-
sion to the available substratum (15). In order to initially assess 
the effects of lactoferrin on neutrophil activation, we performed 
time-lapse video microscopy of neutrophils and recorded directly 
their activation morphology, cell spreading, and locomotion. 
During a 1-hour time course, lactoferrin-pretreated neutrophil 
populations stimulated with fMLP displayed a greater propor-
tion of nonadherent cells as well as cells presenting a rounded, 
nonactivated morphology as compared with neutrophils treated 
with fMLP alone (Figure 6, A and B). These quantitative differ-
ences between lactoferrin-treated and untreated neutrophils 
stimulated with fMLP were reflected in the locomotion of the 
cells around the substratum, with lactoferrin-treated cells dis-
playing markedly reduced movement.
Changes in cell morphology following stimulation with fMLP or 
other neutrophil agonists are characterized by a rapid increase in 
intracellular cytoplasmic calcium levels through mobilization of 
calcium from ER stores and activation of calcium influx channels 
of the plasma membrane, mediated by the inositol triphosphate 
(IP3) and diacylglycerol/PLC (DAG/PLC) pathways (31–33). In order 
to determine whether the observed cell shape alterations following 
lactoferrin treatment are related to changes in intracellular calcium 
concentrations ([Ca2+]i), we measured the levels of [Ca2+]i in control 
and lactoferrin-treated cells in response to fMLP stimulation (1 nM 
or 10 nM). No changes were observed in the fMLP-mediated [Ca2+]i 
response between control and lactoferrin-treated neutrophils, sug-
gesting that lactoferrin acts downstream or independently of the 
mechanisms involved in intracellular calcium flux (Figure 6C).
As lactoferrin was shown to prevent neutrophil migration, we 
next explored whether it could also affect the neutrophil activa-
tion state. To this end, we chose to measure the expression of 2 
Figure 5
Lactoferrin inhibits neutrophil migration in 
vivo. Total cell (A) or neutrophil number (Gr-1+; 
B) obtained from peritoneal lavage. *P < 0.05 
vs. transferrin; †P < 0.05 vs. thioglycollate 
(TG) control, **P < 0.01 vs. transferrin con-
trol. Error bars indicate SEM. (C) Charac-
teristic cytospin images. Original magnifica-
tion, ×400, top; ×200, bottom.
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known neutrophil activation–associated markers, CD62L (L-selec-
tin) and CD11b, using 2-color flow cytometry. Upon activation, 
CD62L is cleaved from the neutrophil surface, whereas CD11b 
expression is upregulated following translocation from cytoplas-
mic granules to the cell membrane. Freshly isolated neutrophils 
were pretreated with lactoferrin and then exposed to the activa-
tion stimuli fMLP, TNF-α, and PMA. As shown in Figure 7, A–D, 
we found that, in lactoferrin-treated neutrophils compared with 
control cells, CD62L expression was significantly higher, whereas 
CD11b levels were lower. These effects were common to all acti-
vation stimuli used. Transferrin-treated neutrophils were also 
included but showed no significant differences compared with 
control cells. It is noteworthy that the lactoferrin effect was also 
evident when PMA, a specific PKC activator, was used as an ago-
nist, indicating that lactoferrin acts downstream of PKC and not 
on pathways involved in PKC activation and Ca2+i responses, such 
as the IP3 and DAG/PLC pathways. This finding prompted us to 
investigate putative downstream targets of PKC involved in the 
late signaling cascades following neutrophil activation that also 
regulate cell motility and actin reorganization. Such cascades 
involve the activation of MAP family kinases (34), and we there-
fore examined the phosphorylation of p44/42 (ERK1 and ERK2) 
MAPKs. Whereas in untreated neutrophils, ERK1 and ERK2 were 
phosphorylated following fMLP stimulation (100 nM), lower levels 
of phosphorylated ERK1/2 were observed in neutrophils that had 
been pretreated with lactoferrin prior to stimulation with fMLP 
(Figure 7E). Collectively, these data suggest that lactoferrin has a 
clear impact on neutrophil activation, including impairment of 
neutrophil degranulation, inhibition of expression of β2 integrins, 
and reduction of activation of intracellular kinases, with profound 
effects on cell migration and motility.
Induction of apoptosis upregulates lactoferrin expression and release 
in diverse cell types. Pursuing our initial hypothesis, which was 
strengthened by early observations that inhibition of neutrophil 
migration by BL cells appeared to be correlated with BL cell apop-
tosis (Figure 1E), we assessed lactoferrin expression following 
induction of apoptosis in a panel of cells of diverse lineages. By 
transcriptional analysis using RT-PCR, we found that lactofer-
rin was expressed, as reported previously (35), by MCF-7 mam-
mary epithelial cells in their viable state but not by Jurkat, BL2, or 
A549 cells. Upon apoptosis induction, lactoferrin expression was 
upregulated in MCF-7 cells and expressed de novo in Jurkat, BL2, 
and A549 cells (Figure 8). More specifically, lactoferrin was tran-
scribed de novo early after induction of apoptosis in A549 cells 
by either 100 nM etoposide or 1 μM staurosporine (Figure 8B). 
Levels of lactoferrin induced by etoposide were reduced in cells 
treated in the presence of the broad-spectrum caspase inhibitor 
zVAD-fmk, which prevented apoptosis induction (Figure 8C). The 
link between lactoferrin expression and apoptosis induction was 
further supported by the effects of the apoptosis inhibitor Bcl-2. 
Figure 6
Effect of lactoferrin on neutrophil polarization morphology and spreading. (A) Time-lapse video microscopy frames of control or lactoferrin-pre-
treated neutrophils (10 μg/ml; 40 minutes at 37°C) stimulated with 1 μM fMLP over a 1-hour incubation time course. Original magnification, ×400. 
(B) Quantification of neutrophils (nonpolarized) counted from 5 different fields; *P < 0.05, **P < 0.01 vs. corresponding +LTF control. Error bars 
indicate SEM. (C) Representative plot (of 3 independent experiments) showing measurement of [Ca2+]i levels in neutrophils incubated in the 
presence or absence of lactoferrin (10 μg/ml; 30 minutes at 37°C) followed by stimulation with 10 nM fMLP.
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BL cells expressing exogenous Bcl-2 that provided protection from 
apoptosis expressed lower levels of lactoferrin upon exposure to 
staurosporine than did their parental counterparts (Figure 8, A 
and D). Not only was apoptosis-related lactoferrin expression dem-
onstrated at the transcriptional level, lactoferrin protein was also 
recovered from supernatants of cells undergoing apoptosis (Figure 
8D). Treatment of A549 cells with brefeldin A, which interferes 
with intracellular transport of newly synthesized proteins, resulted 
in inhibition of apoptosis-induced lactoferrin release, providing 
further evidence for de novo synthesis and secretion of lactoferrin 
by cells undergoing apoptosis (Figure 8E). An analogous effect was 
also evident from supernatants obtained from primary lympho-
cytes induced to become apoptotic in the presence of 1 μM stauro-
sporine. Finally, immunoblotting analyses and chemotaxis assays 
using supernatants of BL cells undergoing primary necrosis fur-
ther revealed that the release of lactoferrin is not linked to necrosis 
but that lactoferrin is expressed and actively released from cells as 
a consequence of activation of their apoptosis program (Figure 8F 
and Supplemental Figure 3).
Discussion
Apoptosis plays a key role in regulating cell populations through 
programmed cell death, an intrinsically non-phlogistic process 
that contrasts with accidental, necrotic cell death, which has pro-
inflammatory consequences. Defining the properties of apoptotic 
cells that contribute to the noninflammatory or antiinflammato-
ry nature of the apoptosis program is critical to our understand-
ing of this fundamental biological process. We have now identi-
fied lactoferrin as a cell-autonomous antiinflammatory mediator 
that is produced by cells of diverse lineages undergoing apoptosis. 
Furthermore, these studies demonstrate a hitherto unrecognized 
immunomodulatory function of lactoferrin: to inhibit directly 
the migration of neutrophil granulocytes. Lactoferrin is therefore 
a constitutive antiinflammatory component of apoptotic cells 
that, in addition to its known antiinflammatory properties, mili-
tates against the proinflammatory recruitment of granulocytes 
to sites of apoptosis.
First discovered in milk almost 70 years ago, lactoferrin is a highly 
pleiotropic iron-binding glycoprotein closely related to transfer-
rin that is a well-known constituent of exocrine secretions and 
secondary granules of neutrophils. It has many antiinflammatory 
and immunoregulatory properties, and the majority of these are 
not related to its ability to chelate iron, although some of its bacte-
riostatic features are dependent on iron binding (36, 37). Its ability 
to inhibit neutrophil migration, as described here, is an additional 
antiinflammatory feature of the molecule that is independent of 
its iron-chelating activity. In addition to its well-established anti-
microbial properties, lactoferrin can inhibit proinflammatory 
responses not only through its ability to bind to key components 
of bacteria and viruses, but also through its direct activity on 
innate immune cells and molecules (36, 37). Thus, lactoferrin can 
inhibit production of proinflammatory mediators such as TNF-α 
and IL-6 (38, 39) and can promote production of antiinflamma-
tory mediators including IL-10, IL-4, and TGF-β1 (40, 41).
The identification of specialized high- or low-affinity lactofer-
rin receptors on human neutrophils provides an initial mechanis-
tic insight into how lactoferrin exerts its inhibitory effect on the 
neutrophil migration machinery. This is in accordance with our 
Figure 7
Effect of lactoferrin on neutrophil activation status. The 
expression of CD62L (A and B) and CD11b (C and D) 
was assessed in fMLP- (100 nM), TNF-α– (1 ng ml), or 
PMA-stimulated (100 nM) neutrophils (30 minutes at 
37°C) that were preincubated (40 minutes at 37°C) in 
the presence or absence of lactoferrin (10 μg/ml). Rep-
resentative flow cytometry overlays of CD62L (A) and 
CD11b (C) expression in control (gray) and stimulated 
neutrophils (lactoferrin-treated: red; untreated: blue). 
n = 3; *P < 0.05, **P < 0.01. Error bars indicate SEM. 
(E) Western blot analysis to determine levels of ERK1/2 
phosphorylation. Neutrophils were incubated with lacto-
ferrin (10 μg/ml; 40 minutes at 37°C), followed by stimu-
lation with fMLP (100 nM) for the indicated times. Mem-
brane was stripped and reprobed for total ERK2. Results 
are representative of 3 independent experiments.
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results demonstrating that lactoferrin binds directly to neutro-
phils and impinges on intracellular signaling events coupled to 
neutrophil activation, rather than interacting with chemoattrac-
tants and modulating their activity. Moreover, the latter possibility 
was further excluded by the fact that the observed inhibitory effect 
of lactoferrin was (a) specific to neutrophil, not monocyte, migra-
tion, (b) observed with a diversity of chemoattractants, and (c) not 
directly neutralized by chemoattractants. Consistent with other 
studies (26, 27), our results demonstrated 2 classes of lactoferrin 
receptor on the surface of human neutrophils. Our results indicate 
that a relatively high-affinity receptor is expressed at relatively low 
density and that a relatively low-affinity receptor is expressed at 
relatively high density. However, the detailed characterization of 
the lactoferrin receptor(s) and dissection of downstream signaling 
pathways remain a significant challenge, as lactoferrin has been 
extensively reported to interact with a range of molecules and 
receptors in a cell-specific manner and therefore has the potential 
to elicit different signaling cascades in different cell types. Indeed, 
many researchers over many years have attempted the detailed 
characterization of lactoferrin receptors from various cell types 
with only partial success, and many candidate receptors have been 
proposed for different cell types. Importantly, as has been sug-
gested elsewhere (42), critical difficulties in the identification of 
specific lactoferrin receptors stem from the cationic nature of the 
lactoferrin protein, allowing it to bind to anionic molecules found 
in virtually all cell types.
Here, we have observed several effects of lactoferrin on cell acti-
vation with clear implications for migration, adhesion, and motil-
ity of neutrophils. The initial phase of neutrophil activation fol-
lowing agonist stimulation is characterized by a rapid increase in 
[Ca2+]i, which in turn triggers the activation of PKC as well as a 
range of calcium-dependent signaling pathways that control key 
neutrophil effector functions, including degranulation, cytoskel-
etal rearrangements, and cell migration (32, 43–45). Our data 
clearly suggest that the observed lactoferrin-mediated inhibitory 
effects on neutrophil chemotaxis could be attributed to modula-
tion of molecules other than those involved in the Ca2+i response 
following agonist stimulation. In addition, analysis of the expres-
sion of early activation markers such as CD62L and CD11b fol-
lowing stimulation with diverse neutrophil agonists, including 
PMA, a specific synthetic intracellular activator of PKC, further 
suggests that lactoferrin acts downstream or independently of the 
PKC pathway, affecting signaling cascade components of the later 
phases of neutrophil activation. This notion was strengthened by 
our observation that lactoferrin inhibited the phosphorylation 
of p44/42 (ERK1 and ERK2) MAPKs, indicating that its action 
is mediated, at least in part, via the MAPK pathway, a key path-
way downstream of PKC with a crucial role in the regulation of 
cytoskeletal rearrangement and cell adhesion (46–48). The previ-
ously reported specific interaction of lactoferrin with the calcium-
calmodulin complex (Ca2+/CaM) provides further insight into the 
potential intracellular signaling targets of lactoferrin (49). The 
Ca2+/CaM complex is formed following the increase in [Ca2+]i and 
PKC activation and regulates the activity of a number of pathways 
involved in cell adhesion and migration, including the ERK1/2 
kinases (50). Indeed, the use of specific inhibitors of calmodulin 
activity has been demonstrated to mimic the effect of lactoferrin 
— inhibition of neutrophil migration — reported here (51–53).
Lactoferrin has been shown previously to bind to receptors on 
mononuclear phagocytes and to inhibit proinflammatory responses 
via NF-κB (39, 54, 55). Taken together with the evidence that 
apoptotic cells can suppress proinflammatory responses of mono-
nuclear phagocytes and can elicit antiinflammatory responses by 
these cells (10, 11), our results indicate that it is now reasonable to 
suspect that these effects are mediated, at least in part, by lactofer-
rin produced by apoptotic cells. However, the involvement of the 
NF-κB pathway in the inhibition of neutrophil migration seems 
unlikely, since lactoferrin-mediated inhibition of chemotaxis of 
Figure 8
Induction of apoptosis upregulates lactoferrin expression and release. (A) RT-PCR analysis in cell lines stimulated to undergo apoptosis (A) and 
unstimulated controls (V). MCF7 cells transfected with caspase-3 (25.4% apoptosis; 100 μM etoposide, 20 hours), Jurkat (18.4% apoptosis; 
1 μM staurosporine, 3 hours), BL2 (12.46% apoptosis), and BL2/Bcl-2 (7.42% apoptosis; 1 μM staurosporine, 1 hour). The lanes were run on the 
same gel but, where indicated by the vertical lines, were noncontiguous. (B) Lactoferrin expression in A549 cells at defined time points (hours) fol-
lowing stimulation with 100 μM etoposide or 1 μM staurosporine. (C) Addition of pan-caspase inhibitor zVAD-fmk (100 μg/ml) for 12 hours in order 
to prevent etoposide-induced apoptosis in A549 cells. (D) Immunoblot analysis of cell supernatants from: BL2 and primary lymphocytes in the 
presence (+) or absence (–) of staurosporine (1 μM) in serum-free conditions for 1 hour. A549 cells were stimulated with (+) or without (–) 100 μM 
etoposide for 5 hours. All samples were run on the same gel. Noncontiguous samples of A549 cells and lymphocytes (Lymph) are indicated 
by the vertical lines. (E) A549 cells were induced to become apoptotic (100 μM etoposide; 20 hours) in the presence or absence of brefeldin A 
(1 μg/ml), a protein release inhibitor. (F) Immunoblot analysis of cell supernatants from control BL2 cells (1 × 106/ml) induced to undergo apop-
tosis (1 μM staurosporine, 1 hour) or primary necrosis (56°C, 1 hour) in serum-free conditions. St, staurosporine; con; control; Etop, etoposide.
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neutrophils treated with gliotoxin, a specific NF-κB inhibitor, was 
found to be identical to that of untreated cells (data not shown). 
In addition, no changes in the levels of IκB, an inhibitor of NF-κB 
that is degraded following NF-κB activation, were observed in 
Western blot analysis of fMLP-stimulated neutrophils treated with 
or without lactoferrin (data not shown).
In general terms, in professional phagocytes, sensing mecha-
nisms that are not yet well defined allow these cells to navigate 
to apoptotic cells through chemotactic processes involving lipid 
signaling molecules and classical chemokine mechanisms (1, 2). 
It is noteworthy that of the 2 categories of professional phago-
cytes — mononuclear (monocytes and macrophages) and polymor-
phonuclear (granulocytes) — apoptotic cells attract mononuclear 
phagocytes selectively (12). Indeed, the lack of recruitment of 
granulocytes to apoptotic zones is a hallmark of the non-phlogis-
tic apoptosis program, distinguishing normal areas of cell death 
from sites of accidental or pathological tissue damage or infection. 
Recent evidence suggests that certain recombinant preparations 
of lactoferrin have the potential to chemoattract monocytes (56). 
Although we failed to observe monocyte attraction to lactoferrin 
in our studies with milk-derived lactoferrin, these results indi-
cate that lactoferrin has the potential to function in the selective 
attraction of monocytes but exclusion of granulocytes from sites 
of apoptosis. Our observation that lactoferrin, released into the 
supernatants of apoptotic cells, is able to inhibit the migration 
of neutrophils, demonstrates not only that physiological concen-
trations of lactoferrin are functional in mediating this effect but 
also that apoptotic cells are active in producing a factor that can 
potently suppress migration of neutrophils, the major subset of 
professional phagocytes among circulating leukocytes, to sites of 
apoptosis. Although it is clear that the secretory events inhibited 
by brefeldin A treatment (transport from the ER and Golgi net-
work) are important for the release of lactoferrin from apoptotic 
cells, further work will be required to elucidate the details of this 
secretory process — including whether lactoferrin is transported 
directly from Golgi membranes for release from the cell surface.
While neutrophils may lack the sensing mechanisms to guide 
them to sites of apoptosis, the constitutive production of a fac-
tor that blocks neutrophil migration to such sites is likely to be 
important when the apoptosis program is activated in the pres-
ence of signals that promote neutrophil recruitment during 
inflammatory responses. In this context, it is noteworthy that 
lactoferrin is active in inhibiting IL-8 production by endothelial 
cells (57). Furthermore, lactoferrin’s ability to inhibit neutrophil 
migration is likely to be important in the resolution of acute 
inflammation. Thus, our results suggest that lactoferrin arising 
from the secondary granules of neutrophils and from apoptotic 
cells constitutes a negative feedback component that limits the 
influx of neutrophils to inflammatory sites. We would speculate 
that neutrophils undergoing apoptosis en route to resolution of 
inflammation would release lactoferrin as do other apoptotic cells 
but would be unlikely to be required to synthesize the protein de 
novo. The negative regulatory activity of lactoferrin described here 
places it as one of the few molecules, alongside lipoxins, netrin-1, 
and annexin-1, that negatively regulate neutrophil migration 
(21, 58, 59). More importantly, based on the high specificity of 
its migration-inhibitory properties to neutrophils, lactoferrin is 
identified here as a promising therapeutic target for a range of 
chronic inflammatory conditions, including vasculitis, pulmonary 
fibrosis, and ischemia/reperfusion injury, that are characterized by 
excessive neutrophil infiltration leading to neutrophil-mediated 
host tissue damage and remodeling (19).
Since the properties of lactoferrin extend well beyond its ability 
to regulate infection, immune responses, and inflammation, the 
link established here between lactoferrin production and apop-
tosis has many additional implications. First, lactoferrin’s ability 
to act as a growth factor (60, 61) extends evidence coupling the 
apoptosis program with tissue repair responses (62, 63). Second, 
additional recent evidence suggests that its protease activity may 
be instrumental in activating the caspase cascade. In particular, 
endogenous lactoferrin has been reported by 2 groups to induce 
apoptosis through activation of caspase-3 (64, 65). It is tempting 
to speculate that the de novo synthesis of lactoferrin by cells trig-
gered to undergo apoptosis in our studies is linked to the initia-
tion of the apoptosis program as well as to its antiinflammatory 
features. Therefore, lactoferrin may have multiple properties in 
apoptosis: (a) regulating the initiation of the program, (b) influ-
encing repair in the tissue microenvironment, and (c) promoting 
the non-phlogistic nature of the process.
Lactoferrin’s functions in relation to tumor biology are cur-
rently unclear. Proteolyzed forms of exogenous lactoferrin have 
been reported to have proapoptotic and antitumor activities. In 
addition, lactoferrin appears to promote antitumor host immune 
responses (37), and activation of antigen-presenting cells has 
recently been reported using high doses of recombinant lactoferrin 
produced in Aspergillus (56). Its observed effects on cell growth are 
inconsistent, and both growth-promoting and growth-inhibiting 
effects have been reported (60, 61, 66, 67), suggesting the possible 
importance of tissue context. Since lactoferrin has potent ability 
to inhibit neutrophil migration, it seems likely that in tumors in 
which neutrophils play a supportive role, limitation of neutrophil 
infiltration through lactoferrin administration could be thera-
peutically beneficial. However, in tumors in which neutrophils are 
absent, we propose that, given the known antitumor effects of neu-
trophils (68–71), encouragement of neutrophil infiltration through 
inhibition of lactoferrin may effect tumor destruction. Our results 
might predict that tumors in which apoptosis is prominent would 
produce lactoferrin in situ. While this suggestion requires proper 
investigation, at least in one category, BL, a high-grade malignancy 
in which high-rate apoptosis occurs, in situ production of lactofer-
rin protein has been known for many years (72).
In conclusion, we describe a novel homeostatic function for the 
highly pleiotropic immunomodulatory glycoprotein lactoferrin. 
We demonstrate that lactoferrin production is closely coupled to 
the fundamental cell death program, apoptosis. In this respect, 
lactoferrin is much more generally expressed than previously real-
ized. Our results show that lactoferrin endows apoptotic cells with 
antiinflammatory properties, including the capacity to inhibit 
neutrophil migration. Given the multifunctional abilities of lac-
toferrin, these results have broad implications for the influence 
of apoptotic cells on multiple physiological processes, including 
cell growth, differentiation, and innate and adaptive immune 
responses, as well as the pathological processes of inflammatory 
and malignant diseases.
Methods
Antibodies and reagents. The following antibodies and reagents were used in 
this study: rabbit polyclonal anti–human lactoferrin IgG antibody (Sigma-
Aldrich), mouse monoclonal anti–human lactoferrin antibodies (LF-2B8, 
AbD Serotec; imab75 and imab77, ImmunoSolv), rabbit polyclonal immu-
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noglobulin (IgG) negative control (Dako), IgG1 isotype control (Sigma-
Aldrich), allophycocyanin-conjugated (APC-conjugated) anti-CD11b 
(mIgG1; BD), FITC-conjugated anti-CD62L (mIgG1; AbD Serotec), puri-
fied human lactoferrin from milk (Sigma-Aldrich), purified human lacto-
ferrin from neutrophils (Athens Research and Technology), recombinant 
human lactoferrin (Sigma-Aldrich), human recombinant apolactoferrin/
hololactoferrin (ProSpec), purified human transferrin (Sigma-Aldrich), 
recombinant human TNF-α (R&D Bioscience), PMA (Sigma-Aldrich), 
fMLP (Sigma-Aldrich), C5a (Sigma-Aldrich), IL-8 (Sigma-Aldrich), LTB4 
(Sigma-Aldrich), brefeldin A (Sigma-Aldrich), staurosporine (Sigma-
Aldrich), and gliotoxin (Sigma-Aldrich). For lactoferrin absorption che-
moattractants, each chemoattractant was incubated with purified human 
milk lactoferrin (10 μg/ml), and a mouse monoclonal anti–human lacto-
ferrin antibody (LF-2B8; 10 μg/ml) or isotype control was added. Antibod-
ies were completely removed by BioMag goat anti–mouse IgG (QIAGEN) 
magnetic beads, and the efficiency of antibody removal was assessed by 
analysis of the preabsorbed chemoattractants by anti–mouse IgG ELISA 
(data not shown). Furthermore, the depleted antibody was readily recov-
ered from the beads (data not shown).
Cell isolation. Fresh human venous blood was collected from volunteers 
according to the Royal Infirmary of Edinburgh (Scotland) Research Eth-
ics Committee (approval 1702/95/3/11), and mononuclear and polymor-
phonuclear (PMN) leukocytes were isolated as previously described (73). 
Neutrophils represented more than 95% of isolated PMN cells. Monocytes 
(>90% CD14+ cells) were positively selected from isolated mononuclear 
leukocytes using CD14 magnetic beads (Miltenyi Biotec). Human mono-
cyte–derived macrophages were obtained following culture of monocytes 
for 6 days in Iscove’s modified Dulbecco’s medium (IMDM) containing 
10% autologous serum.
Chemotaxis assay. In vitro leukocyte chemotaxis was measured following 
a well-established transfilter cell migration assay, as previously described 
(12) using polyvinyl uncoated Transwell inserts (5 μm pore size; Costar, 
Corning). Time of incubation (37°C; 5% CO2) varied for cell type (neu-
trophils: 60 minutes; monocytes: 90 minutes; macrophages: 4 hours). 
Unless otherwise stated, lactoferrin was used at 10 μg/ml. Chemotactic 
agents included fMLP (100 nM; Sigma Aldrich), C5a (6.25 ng/ml; Sigma 
Aldrich), IL-8 (50 nM; R&D Systems), and LTB4 (100 nM; Sigma Aldrich). 
For neutralization experiments, rabbit polyclonal anti–human lactoferrin 
antibody (Sigma Aldrich) or negative control (Dako) were used. Filters were 
observed using an inverted microscope (Zeiss Axiovert 25), and relative cell 
migration was determined by enumerating the number of migrated cells 
in 10 random high-power (×400) fields.
shRNA lentiviral transduction of BL cells. Lactoferrin expression was downreg-
ulated using shRNA lentiviral vectors (MISSION; Sigma-Aldrich). Briefly, 
lactoferrin-targeted shRNA lentiviral plasmids (pLKO.1-puro) were cotrans-
fected with ViraPower Lentiviral packaging mix (pLP1, pLP2, pLP-VSV-G; 
Invitrogen) to 293FT cells using Lipofectamine LTX (Invitrogen). BL2 cells 
were transduced with the shRNA-expressing lentivirus, and stable cell lines 
were generated by selection with puromycin (2 μg/ml; Sigma-Aldrich).
RT-PCR analysis. Total RNA was extracted (RNeasy kit; QIAGEN) and 
reverse transcribed (2 μg) using SuperScript III RT (Invitrogen). Result-
ing cDNAs were used as template in PCR experiments at a concentration 
of 1 ng/50 μl of PCR mixture. The primers used were: forward lactoferrin 
(5′-TGTCTTCCTCGTCCTGCTGTTCCTCG-3′) and reverse lactoferrin 
(5′-CTGCCTCGTATATGAAACCACCATCAA-3′), forward GAPDH primer 
(5′-CGACAGTCAGCCGCATCTTCTTTTGCGTCG-3′) and reverse GAPDH 
primer (5′-GGACTGTGGTCATGAGTCCTTCCACGATAC-3′). Cycle param-
eters (lactoferrin: 40 cycles; GAPDH: 28 cycles) were: denaturation 94°C for 
1 minute, primer annealing at 67°C (lactoferrin) or 50°C (GAPDH) for 1 min-
ute, and extension at 72°C for 45 seconds, with a first denaturation step at 
94°C for 7 minutes and a final extension at 72°C for 5 minutes. Purified PCR 
products (QIAquick gel extraction kit; QIAGEN) were sequenced to confirm 
validity by the Sequencing Service of the School of Life Sciences, University 
of Dundee, using Applied Biosystems BigDye 3.1 chemistry on an Applied 
Biosystems model 3730 automated capillary DNA sequence analyzer.
Peritonitis model. All animal procedures were carried out under a UK 
Home Office Animals (Scientific Procedures) Act 1986 project licence. Mice 
(8- to 12-week-old female C57BL/6 mice; n = 7 per group) were injected i.p. 
with purified human lactoferrin or transferrin (500 ng in saline/0.1%; BSA 
Sigma Aldrich) or saline/0.1% BSA alone followed by a second i.p. injec-
tion with 1% thioglycollate (500 μl) or saline/0.1% BSA after 20 minutes. 
Recruited leukocytes were harvested after 4 hours by peritoneal lavage with 
ice-cold saline containing 2 mM EDTA. Harvested cells were counted using 
a NucleoCounter (ChemoMetec), which excluded nonnucleated cells. To 
determine the number of neutrophils (Gr-1+), cells were immunolabeled 
with PE-conjugated anti-mouse Ly6–Gr-1 and counted using Flow-Count 
beads (Beckman Coulter).
Histology and immunohistochemistry. Six- to 10-week-old BALB/c SCID mice 
were injected i.p. with 107 BL2 cells. Tumors developed i.p. within 2 months 
of injection. Mice were sacrificed and tumors excised. For positive control, 
BALB/c mice were immunized with sheep red blood cells and spleens har-
vested and frozen 7 days after i.p. injection. Immunohistochemistry was 
performed on frozen acetone-fixed sections (5 μm) of BL or spleen tissues 
using biotinylated anti–mouse Gr-1 antibody (10 μg/ml; BioLegend) or 
isotype control (AbD Serotec). Nonspecific adsorption of antibodies was 
blocked using serum-free Protein Block (Dako). Reactions were amplified 
using VECTASTAIN Elite ABC avidin-biotinylated peroxidase complexes 
(Vector Laboratories). Hematoxylin was used as counterstain.
Flow cytometry. Unless otherwise stated, cells were suspended in PBS 
containing 5% normal mouse serum or 0.1% BSA, and all antibody incu-
bations were performed for 20 minutes on ice. Mouse neutrophils were 
defined based on the expression of Gr-1 epitope using PE-conjugated rat 
anti–mouse Ly6G (Gr-1; eBioscience). For the assessment of neutrophil 
activation, the following antibodies were used: FITC-conjugated anti-
CD62L (FMC46, mIgG2b; AbD Serotec) and APC-conjugated anti-CD11b 
(ICRF44, mIgG1; BD). Isotype controls included mouse IgG1:FITC (AbD 
Serotec), mouse IgG1:APC (BD), and rat IgG2b:PE (eBioscience). Cell apop-
tosis was determined by labeling with annexin V and propidium iodide. 
Samples were analyzed using a BD FACSCalibur or FACScan cytometer, 
and data were analyzed using BD CellQuest software.
Size fractionation and ion exchange chromatography. Size fractionation of BL2 
cell conditioned media was performed using filters with specific molecular 
weight cutoff sizes (Amicon Centrifugal filters YM-50 and YM-100; Milli-
pore), following the manufacturer’s instructions. Ion exchange chromatog-
raphy was carried out using Q Sepharose Fast Flow beads (Sigma-Aldrich). 
Beads were washed with neutralizing buffer, and bound proteins were then 
eluted by addition of 10 mM NaAc, 0.5 M NaCl, pH 4. BL2 cell–condi-
tioned medium or control medium (RPMI 1640) was mixed with the beads 
and incubated at room temperature for 5 minutes. Samples were centri-
fuged (300 g, 5 minutes) and supernatants stored. Beads were washed with 
neutralizing buffer, and bound proteins were then eluted by addition of 
the corresponding elution buffer (for S beads: 10 mM Tris, 0.5 M NaCl, 
pH 10; for Q beads: 10 mM NaAc, 0.5 M NaCl, pH 4). After a 5-minute 
incubation at room temperature, beads were centrifuged (300 g, 5 minutes) 
and supernatants collected and analyzed. Prior to chemotaxis analysis, the 
supernatants were diluted (1:100), and pH was adjusted to 7.0. Proteins 
were identified by peptide mass fingerprinting using MALDI-TOF mass 
spectrometry. The procedure was carried out by the Scottish Instrumenta-
tion and Resource Centre for Advanced Mass Spectrometry (SIRCAMS), 
School of Chemistry, University of Edinburgh.
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Immunoblotting. Conditioned media from viable and apoptotic BL2 and 
A549 cells were collected, and their protein content was TCA precipitated. 
Briefly, 100 μl TCA was added in 1 ml conditioned medium at 4°C. Sam-
ples were centrifuged at 18,000 g and the pellets washed in ice-cold acetone 
before resuspension in sample buffer (NuPAGE; Invitrogen). Neutrophils 
(5 × 106 cells/ml) were lysed for 15 minutes with 1% NP-40 in TBS con-
taining protease inhibitor cocktail (Sigma Aldrich), aprotinin, leupeptin, 
pepstatin A, 4-(2-aminoethyl)benzenesulfonyl fluoride, sodium orthovan-
adate, benzamidine, levamisole, and β-glycerophosphate. Samples were 
centrifuged (20,000 g, 4°C, 15 minutes) and resolved by SDS-PAGE using 
4%–12% Bis-Tris gels (NuPAGE; Invitrogen). Proteins were then electroblot-
ted onto a nitrocellulose membrane (NuPAGE; Invitrogen), blocked with 
0.5% (for lactoferrin) or 3% BSA (for ERK), and probed with monoclonal 
mouse anti–human lactoferrin (1:100; LF.2B8; AbD Serotec) or mouse 
monoclonal anti-MAPK activated (diphosphorylated ERK1 and ERK2) 
antibody (1:1,000; Sigma-Aldrich) or polyclonal mouse ERK2 (1:1,000; 
Santa Cruz Biotechnology Inc.) or rabbit monoclonal anti-IκBα (74) 
(1:2,500; E130; Abcam) followed by HRP-conjugated goat anti–mouse IgG 
(1:2,000; Amersham) or HRP-conjugated goat anti–rabbit IgG (1:2,500; 
Dako) and visualized using ECL (GE Healthcare).
Binding studies. Biotinylation of human milk–derived lactoferrin was per-
formed using EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Thermo Scientific). 
Fresh neutrophils were exposed to biotinylated lactoferrin (10 μg/ml) at 37°C 
for 1 hour, after which the cells were washed and lysates prepared, resolved by 
SDS-PAGE, electroblotted, blocked with 0.1% PBS-Tween, and probed with 
HRP-conjugated streptavidin (Dako). For Scatchard analyses, 125I-labeled 
human milk–derived lactoferrin, prepared using Pierce Iodination Reagent 
(Thermo Scientific), was added at a constant amount to fresh human neu-
trophils in the presence of increasing amounts of cold, unlabeled lactoferrin. 
After 30 minutes at 4°C, cells were washed 3 times before gamma counting.
Measurement of [Ca2+]i. Measurement of [Ca2+]i was performed as previ-
ously described (75). Briefly, freshly isolated neutrophils were resuspended 
(107/ml) in HBSS (without Ca2+/Mg2+) and were incubated with 2 μM 
FURA 2/AM (Calbiochem) at 37°C for 30 minutes. The cells were washed 
twice, resuspended at 2 × 106/ml in HBSS (with Ca2+/Mg2+), incubated 
for an additional 30 minutes at 37°C in the presence of lactoferrin 
(10 μg/ml), and then stimulated with fMLP (1 nM or 10 nM). [Ca2+]i lev-
els were determined based on 340:380 nm dual wavelength excitation in a 
PerkinElmer luminescence spectrometer at 37°C with constant stirring. 
Calibration was performed after each experiment using Triton X (Rmax) and 
EGTA (Rmin) (Rmax and Rmin are the maximum and minimum 340:380 fluo-
rescence ratios, respectively). [Ca2+]i was calculated based on the 340:380 
nm fluorescence ratio.
Statistics. Results from multiple experiments are presented as mean ± SEM. 
One-way ANOVA was performed, followed by Bonferroni’s post-hoc test. In 
all cases, P values of 0.05 or less were considered significant.
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